Revvity, Inc., provider of Health Science Solutions and Technologies. (NYSE: RVTY) reported revenue growth and adjusted profit for the first quarter 2025 on Monday.
- Revvity reported revenue of $665 million in the March quarter, compared to $650 million in the same period last year.
- In the Life Sciences segment, revenue and organic revenue increased by 1% and 2% over the course of three months
- Diagnostic revenue rose 3% year-on-year in the first quarter, while diagnostic organic revenue rose 5%
- Reported revenue increased per share from $0.21 for the previous year period to $0.35 for the first quarter
- Adjusted earnings from continuing operations were $1.01 per share in the first quarter, but $0.98 per share in the first quarter.
- Operating profit margin from continuing operations was 10.9% as a percentage of revenue compared to 6.8% for the annual quarter.
- The company has increased its full-year revenue guidance to the $283-$2.87 billion range, reflecting recent changes in foreign currency exchange rates.
- Reconfirmed earnings per share guidance adjusted to the $4.90 and $5.00 range
